Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Other CETP Inhibitors Could Escape Torcetrapib Trap, ACC Studies Suggest

Executive Summary

The failure of Pfizer's torcetrapib need not be the death knell of the cholesteryl ester transfer protein inhibitor class, according to analysis of imaging studies presented at the American College of Cardiology Scientific Sessions, because there are several plausible reasons that the lack of efficacy could be due to molecule-specific problems

You may also be interested in...



Time, And Price, Are Right To Prescribe Statins To the Masses

With cheap, proven statins aplenty, cost constraints are “off the table” when it comes to vastly broadening primary prevention, authors of new cholesterol guidelines say at the 2013 AHA meeting. However, evidence for drugs to lower triglycerides and boost HDL is lacking, and focus should be on lifestyle change, they say.

CETP Trials Still Inhibited As Torcetrapib Results Fail To Illuminate Outcomes

The much anticipated results from Pfizer's failed torcetrapib trials did little to illuminate the cause of adverse outcomes in cholesteryl ester transfer protein inhibition, leaving an expectant industry with a charge to start more clinical trials

Cholesterol Playing Field Expands To Early Atherosclerosis, HDL, Novel Drugs

Pfizer is hoping to use the results of its failed torcetrapib trials as additional evidence of Lipitor's efficacy in halting progression of atherosclerosis, while competitor AstraZeneca offers new data to expand Crestor's use into early atherosclerosis

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel